Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 4/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22296709 | 0.84 | SMN1; SMN2 (0.47) | THRATHRBDPP4GRIN2DGRIN2A | |
| SCHEMBL7605422 | 0.84 | GSK3B (0.53) | GSK3BPTPN1THRATHRBDPP4 | |
| SCHEMBL4818283 | 0.81 | GSK3B (0.57) | GSK3BPTPN1 | |
| SCHEMBL8834346 | 0.81 | DPP4 (0.46) | DPP4GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL104594 | 0.79 | GRIN2D (0.57) | THRBGRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL12018041 | 0.79 | KMT2A (0.57) | GRIN2DGRIN2AGRIN2BGRIN2CMEN1 | |
| SCHEMBL2153706 | 0.79 | L3MBTL1 (0.62) | GSK3BPTPN1THRATHRBKMT2A | |
| SCHEMBL11386007 | 0.79 | GRIN2D (0.36) | DPP4GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL8293310 | 0.78 | DPP4 (0.56) | DPP4GRIN2DGRIN2AGRIN2BGRIN2C | |
| SCHEMBL25516477 | 0.78 | KDM4E (0.44) | DPP4GRIN2DGRIN2AGRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507754-A1 | ALKOXY ARYL BETA-2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-6747043-B2 | TREATING PULMONARY DISEASE, PRE-TERM LABOR, NEUROLOGICAL DISORDERS, CARDIAC DISORDERS, AND INFLAMMATION | THERAVANCE, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20040006102-A1 | Alkoxy aryl beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-01-08 | — | — | US | disclosed |
| WO-2003099764-A1 | ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006102-A1 | Alkoxy aryl beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2C | GSK3B 1339/4885PTPN1 2354/4885THRA 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.